RxDoctor Payments Data

Sushma Sadasivan, MD

Family Medicine · Novi, MINPI 1609843739

Payments from drug & device makers

$4,438in general payments, 2019–2025

Across 279 payments — averaging $15.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$670
  • AstraZeneca$664
  • Amgen$396
  • Pfizer$361
  • Boehringer Ingelheim$267
  • Johnson & Johnson$267
  • plus $2K from 27 others

What the payments were for

  • Food & beverage$4,38899%
  • Education$501%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,438 in reported general payments places this provider in the 90th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$34,567
Medicare patients
144
Services billed
505

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide61$75,853
MounjaroTirzepatide20$27,984
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog12$25,254
JardianceEmpagliflozin12$20,614
EliquisApixaban22$19,569
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$15,166
FarxigaDapagliflozin Propanediol12$12,939
AbrysvoRsv Vacc, Pref A And Pref B/Pf38$12,134
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$6,206
ShingrixVaricella-Zoster Ge/As01b/Pf19$4,094
Levothyroxine Sodium262$3,375
Novolog FlexpenInsulin Aspart16$2,897
Atorvastatin Calcium271$2,881
Ezetimibe-SimvastatinEzetimibe/Simvastatin22$2,864
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate12$2,301

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$670$75,85361 claims
PfizerEliquis, Abrysvo$361$31,70360 claims
Lilly USA, LLCMounjaro$252$27,98420 claims
Boehringer IngelheimJardiance$267$20,61412 claims
GSKTrelegy Ellipta, Shingrix$243$19,26034 claims
AstraZenecaFarxiga$664$12,93912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Novi

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →